Ocugen Eyes Broad Retinitis Pigmentosa Indication With One Gene Therapy
Executive Summary
Emerging Company Profile: Turning to gene therapy after its dry eye drug didn’t work out, Ocugen hopes to overcome financial challenges to bring a gene therapy into the clinic for numerous mutations of RP.